AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol

BMJ Open

Volumn 7, Issue 1, 2017, Pages

  Eisen, Damon P ^a,b,c   Moore, Elizabeth M ^c   Leder, Karin ^c,d   Lockery, Jessica ^c   McBryde, Emma S ^b   McNeil, John J ^c   Pilcher, David ^c,e,f   Wolfe, Rory ^c   Woods, Robyn L ^c  

^a TOWNSVILLE HOSPITAL   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f Australian and New Zealand Intensive Care Society   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BLOODSTREAM INFECTION; CLINICAL OUTCOME; CLINICAL PROTOCOL; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LOW DRUG DOSE; MENINGITIS; PERITONITIS; PNEUMONIA; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; AGED; ANTISEPSIS; AUSTRALIA; CONTROLLED STUDY; FEMALE; INFLAMMATION; MALE; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTISEPSIS; ASPIRIN; AUSTRALIA; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION; INTENSIVE CARE UNITS; MALE; RESEARCH DESIGN; SEPSIS;

EID: 85010369533     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-013636     Document Type: Article

References (45)

1. World Health Organisation. The top 10 causes of death. 2014. http://www.who.int/mediacentre/factsheets/fs310/en/index.html
2. Global Burden of Diseases Study, Mortality, Causes of Death Committee. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71.
3. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-10.
4. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.
5. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 2015;15:581-614.
6. Goodman SG, Menon V, Cannon CP, et al. Acute ST segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl 6):708S-75S.
7. Eisen DP. Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis. Intensive Care Med 2012;38:1249-57.
8. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9.
9. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58.
10. Serhan CN, Haeggström JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J 1996;10:1147-58.
11. Serhan CN, Chiang N. Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. Scientific World Journal 2002;2:169-204.
12. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005;102:7671-6.
13. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004;200:69-78.
14. Chiang N, Bermudez EA, Ridker PM, et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004;101:15178-83.
15. El Kebir D, József L, Pan W, et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 2009;180:311-19.
16. Hennekens CH, Schneider WR, Pokov A, et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 2010;15:344-8.
17. Morris T, Stables M, Hobbs A, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009;183:2089-96.
18. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost 2011;9:1097-107.
19. Masotti G, Galanti G, Poggesi L, et al. Differential inhibition of prostacyclin production and platelet aggregation by aspirin in humans. Adv Prostaglandin Thromboxane Res 1980;6:317-20.
20. Huang ES, Strate LL, Ho WW, et al. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011;124:426-33.
21. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:209-16.
22. Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med 2012;40:1761-7.
23. Lösche W, Boettel J, Kabisch B, et al. Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?. Thrombosis 2011;2012:720254.
24. Winning J, Neumann J, Kohl M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010;38:32-7.
25. Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009;20:50-7.
26. Chen W, Janz DR, Bastarache JA, et al. Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Crit Care Med 2015;43:801-7.
27. Otto GP, Sossdorf M, Boettel J, et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 2013;24:480-5.
28. Valerio-Rojas JC, Jaffer IJ, Kor DJ, et al. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract 2013;2013:782573.
29. Boyle AJ, Di Gangi S, Hamid UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care 2015;19:109.
30. Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc 2015;4:e001595.
31. Sossdorf M, Otto GP, Boettel J, et al. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care 2013;17:402.
32. Tsai MJ, Ou SM, Shih CJ, et al. Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med 2015;41:806-13.
33. Al Harbi SA, Tamim HM, Al-Dorzi HM, et al. Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study. BMC Pharmacol Toxicol 2016;17:5.
34. Wiewel MA, de Stoppelaar SF, van Vught LA, et al. Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: a propensity-matched analysis. Intensive Care Med 2016;42:352-60.
35. ASPREE Investigators Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 2013;36:555-64.
36. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
37. Calandra T, Cohen J. International Sepsis Forum Definition of Infection in the ICUCC. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-48.
38. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
39. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing healthcare-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53:1-36.
40. Centers for Disease Control. CDC/NHSN Surveillance Definitions for Specific Types of Infections. Secondary CDC/NHSN Surveillance Definitions for Specific Types of Infections. 2016. http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef-current.pdf
41. Centers for Disease Control. Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and Other Urinary System Infection [USI]) Events. Secondary Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) and Other Urinary System Infection [USI]) Events. 2016. http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef-current.pdf
42. Gunderson CG. Cellulitis: definition, etiology, and clinical features. Am J Med 2011;124:1113-22.
43. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633-8.
44. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63: e1-37.
45. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.